文献速递角膜与眼表疾病

1096例临床病例的启示:开创春季角结膜炎管理的通用分级系统

Insights from 1096 clinical cases: pioneering a universal grading system for vernal keratoconjunctivitis management.
PubMed 文献 · Br J Ophthalmol · 2025-06-23

该研究回顾分析了2015年1月至2020年1月印度1096例春季角结膜炎(VKC)患者的临床与人口学资料,提出一种基于角膜状态和症状周期性而非疾病活动度的VKC分级系统。混合型VKC最常见(52.04%),并发症包括圆锥角膜(18.43%)、激素性白内障(11.41%)、青光眼(10.95%)和角膜缘干细胞缺乏(5.29%)。作者认为该分级系统可能有助于更好地制定管理方案。

要点

  • VKC患者平均起病年龄7.05±5.3岁,成人起病占8.39%。
  • 混合型VKC最常见(52.04%),49.1%的患者为活动性疾病。
  • 双效抗过敏药最常用(69.39%),其次为局部免疫调节剂。

核心结论

  • VKC是一种常引起视力并发症的慢性疾病,基于角膜状态和症状周期性而非疾病活动度的新分级系统可能有助于更好地制定管理方案。

研究设计与样本

  • 回顾性观察研究,纳入2015年1月至2020年1月印度1096例由角膜专科医生诊断的VKC患者,基于既往/现有临床体征和症状频率而非疾病活动度进行分级。

主要发现

  • 患者平均起病年龄7.05±5.3岁,8.39%为成人起病。
  • 症状包括瘙痒(50.55%)和视力下降(15.44%)。
  • 混合型VKC最常见(52.04%),49.1%的患者为活动性疾病。
  • 并发症包括圆锥角膜(18.43%)、激素性白内障(11.41%)、青光眼(10.95%)和角膜缘干细胞缺乏(5.29%)。
  • 双效抗过敏药最常用(69.39%),其次为局部免疫调节剂。

关键数值与推荐

  • I级(轻度):存在轻度和季节性症状和/或体征。
  • II级(中度):存在持续性症状和/或体征,无角膜受累。
  • III级(重度):慢性持续性症状和/或间歇性体征伴角膜受累,或无症状至轻度症状伴角膜特征性体征。
  • IV级(极重度):慢性持续性症状和/或角膜特征性体征或活动性受累/并发症,或无症状伴并发症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To analyse the clinical and demographic profiles of patients with vernal keratoconjunctivitis (VKC) and propose a grading for VKC based on corneal status and symptom periodicity rather than disease activity. METHODS: Retrospective observational study from January 2015 to January 2020 in India. VKC grading was based on past/present clinical signs and frequency of symptoms rather than disease activity. The electronic medical records were screened and details of VKC patients diagnosed by cornea specialists were recorded and analysed. RESULTS: 1096 VKC patients with a mean age of onset of 7.05±5.3 with 8.39% having adult onset were analysed. Symptoms included; itching (50.55%) and decreased vision (15.44%). Mixed VKC (52.04%) was the most common presentation with 49.1% having active disease. Complications included; keratoconus (18.43%), steroid-induced cataract (11.41%), glaucoma (10.95%) and limbal stem cell deficiency (5.29%). Dual-acting antiallergics (69.39%) were most commonly used, followed by topical immunomodulators.The patients were graded as, grade I: mild-presence of mild and seasonal symptoms and/or signs. Grade II: moderate-presence of persistent symptoms/and/or signs without corneal involvement. Grade III: severe-chronic persistent symptoms/and/or intermittent signs with corneal involvement or asymptomatic to mild symptoms with corneal pathognomonic signs. Grade IV: very severe-chronic persistent symptoms and/or corneal pathognomonic signs or active involvement/complication or asymptomatic with complications. CONCLUSION: VKC is a chronic disease that often causes visual complications. The new grading system based on the cornea status and symptom periodicity rather than disease activity might help plan the management better.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Chandrasekar A, Agarwal S, Chauhan G, et al. Insights from 1096 clinical cases: pioneering a universal grading system for vernal keratoconjunctivitis management. Br J Ophthalmol. 2025. PMID: 39880668. doi:10.1136/bjo-2024-325762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。